Efficacy and safety of expanded hemodialysis in hemodialysis patients: a meta-analysis and systematic review

Background: Expanded hemodialysis (HDx) is a new dialysis modality, but a systematic review of the clinical effects of using HDx is lacking. This systematic review and meta-analysis aimed to assess the efficacy and safety of HDx for hemodialysis (HD) patients. Methods: PubMed, the Cochrane library, and EMBASE databases were systematically searched for prospective interventional studies comparing the efficacy and safety of HDx with those of high flux HD or HDF in HD patients. Results: Eighteen trials including a total of 853 HD patients were enrolled. HDx increased the reduction ratio (RR) of beta 2-microglobulin (SMD 6.28%, 95% CI 0.83, 1.73, p= .02), kappa FLC (SMD 15.86%, 95% CI 6.96, 24.76, p = .0005), and lambda FLC (SMD 22.42%, 95% CI, 17.95, 26.88, p < .0001) compared with high flux HD. The RR of beta 2-microglobulin in the HDx group was lower than that in the HDF group (SMD -3.53%, 95% CI -1.16, -1.9, p < .0001). HDx increased the RRs of kappa FLC (SMD 1.34%, 95% CI 0.52, 2.16, p= .001) and lambda FLC (SMD 7.28%, 95% CI 1.08, 13.48, p = .02) compared to HDF. There was no significant difference in albumin loss into the dialysate between the HDx and HDF groups (SMD 0.35g/session, 95% CI -2.38, 3.09, p = .8). Conclusions: This meta-analysis indicated that compared with high-flux HD and HDF, HDx can increase the clearance of medium and large-molecular-weight uremic toxins. And it does not increase the loss of albumin compared with HDF.

Automated summary

HDx improves the clearance of medium and large-molecular-weight uremic toxins compared to high-flux HD and HDF, without increasing albumin loss.